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 Main Text 
 
Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN or NBIA4) is caused by 
biallelic mutations in the C19orf12 gene. MPAN accounts for the largest proportion of NBIA after 
PKAN (PANK2 mutations) and PLAN (PLA2G6 mutations). It is characterized by juvenile-onset 
spastic paraparesis, levodopa-unresponsive parkinsonism, dystonia and neuropsychiatric symptoms. 
Additional features are optic atrophy, dysphagia, dysarthria, and motor axonal neuropathy. Brain 
MRI displays T2-weighted symmetrical hypointensities in globus pallidus (GP) and substantia nigra 
(SN) [1]. Missense, frameshift and nonsense mutations were found in exons 2 and 3 of C19orf12 
(NM_001031726 transcript). One splice-site mutation (c.194-2A>G) was identified in intron 2 
(Figure 1a). Specific variants were found to be frequent in MPAN cases of selected populations 
(c.204_214del - p.G69Rfs*10 in Eastern Europeans and p.T11M in Turkish) [2, 3]. Here we report 
a case of NBIA with a novel C19orf12 mutation with molecular evidence of de novo occurrence 
The relevant ethical authorities approved the study and written informed consent was obtained from 
all involved subjects. The proband is the only child of non-consanguineous Italian parents. Familial 
history was negative for neurological disorders (Figure 1b). She was born at term by spontaneous 
delivery after an uneventful pregnancy. Motor development was at first normal, while a delay in 
language development was reported at the age of 3. Height-weight growth has been always at the 
lower normal limits (3-10 centiles). At the age of 5 she developed a progressive imbalanced gait 
associated with lower limbs rigidity and later onset of right hand dystonia forced her to use the left 
hand to write. She developed mild hirsutism at 9 years (pubis and limbs) and precocious puberty. 
Ocular involvement was present and included low vision, hypermetropia and astigmatism. She 
attends high school with a support teacher for learning disability (IQ 74). She came to the attention 
of our outpatient clinic at the age of 16 years. The neurological examination showed moderate 
dysarthria, cervical dystonia, dysdiadochokinesia, mild intentional and postural upper limbs tremor, 
lower limbs spastic hypertonia associated with movement-exacerbated dystonic postures of feet, 
 patellar hyperreflexia and bilateral Babinski sign. Typical radiological findings of SN and GP 
hypointensity in SWI, T2* and T2-weighted MRI with a T2-hyperintense medial medullary lamina 
(MML) were present, with the additional finding of subthalamic nucleus involvement. No cortical 
or cerebellar atrophy was evident (Figure 1d). Electroencephalogram and electroretinogram were 
normal, while visual evoked potential displayed an increased latency of P100 wave bilaterally with 
reduced amplitude and EMG showed diffuse axonal motor neuropathy. Fundus examination 
revealed optic atrophy. 
Genetic analysis revealed a novel heterozygous C19orf12 c.265_266delAT (NM_001031726) - 
p.M89Gfs*12 (NP_001026896) mutation in the proband, but not in her parents (Figure 1b-c). False 
paternity was excluded using eight polymorphic short tandem repeats (STR) on chromosome X. 
This suggests the p.M89Gfs*12 being a de novo mutation. Sanger sequencing of all exons and 
intron-exons boundaries of PANK2, PLA2G6, C19orf12, FA2H, WDR45, COASY, CP, and FTL, 
and full-length amplification followed by sequencing of PANK2 and WDR45 transcript did not 
detect other pathogenic mutations or rearrangements. 
The amount of C19orf12 transcripts was measured by quantitative reverse-transcription PCR in 
lymphocytes of patient, parents and controls. This assay failed to detect a reduced mRNA quantity 
in the proband cDNA, suggesting the absence of degradation through nonsense-mRNA decay. 
Sequence analysis of C19orf12 transcripts revealed the presence of the heterozygous 
c.265_266delAT mutation in the proband and ruled-out splicing aberrations on both mutated and 
non-mutated alleles. 
In order to explore a possible mosaicism, the mutation was studied in DNA from several tissues 
(hair, saliva and urine). The presence of the p.M89Gfs*12 in all tissues suggests a germ-line 
mosaicism in a parent. 
MPAN  is   considered  an  autosomal   recessive   disorder;   however,  five   monoallelic C19orf12 
 
mutations have been already described [1, 3, 4].   A second occult mutation was suspected to be 
 present in these cases. Deletion screening and promoter regions sequencing in some of these cases 
did not identified a second mutation [1, 3, 4]. Interestingly, all these mutations localize on exon 3 
(G69R, p.Q86*, p.A94Cfs*8, p.A120Gfs*32 and p.L99fs*102), including deleterious 
frameshift/stop mutations on the C19orf12 C-terminal domain, as in the case described in this  
study. Moreover, in a family with a heterozygous p.A120Gfs*32 mutation family history suggested 
a possible autosomal-dominant inheritance; indeed, the father of the patient, who died at age 47 
following a long course of progressive dementia with parkinsonism, showed a typical MPAN 
neuropathology at postmortem examination [3]. 
Several lines of evidence support the pathogenic role of the identified variant reported here: the 
association with clinical-radiological features of MPAN, the de novo occurrence of the variant, the 
lack of additional mutations or aberrant splice sites on C19orf12 transcripts and the absence of 
genetic mutations in other NBIA genes. The lack of a second mutation may indicate a dominant 
negative effect of this variant. Alternatively, the combination of this p.M89Gfs*12 with mutations 
in other still unknown causative genes may be hypothesized. In this view, studies on additional 
MPAN cases with monoallelic mutations are required in order to explore their role in NBIA. 
 
 
 
Figure Legend 
 
A) Representation of the C19orf12 gene mutations reported in MPAN phenotypes so far. B) 
Pedigree of the family under study. Black symbol denotes affected individual. C) 
Electropherograms of the mutation c.265_266delAT of C19orf12 gene in the proband (II.1) and 
wild type sequence in her parents (I.1 and I.2). D) Patient Brain MRI (T2, FLAIR and SWI 
sequence), performed at the age of 16, showing hypointensity of substantia nigra, globus pallidus 
and interestingly, subthalamic nucleus. (Abbreviations: wt =Wild type; mut = Mutated; GP = 
Globus Pallidus; GPe = External Globus Pallidus; GPi = Internal Globus Pallidus; SN = Substantia 
Nigra; STN = Subthalamic nucleus; MML = Medial Medullary Lamina). 
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